Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Vijay Kumar
Period: Reporting periods mapped to calendar 2024 Q3 – 2026 Q3 (9 quarters).
- Questions
- 154on tracked calls
- Challenge rate
- 16%25 of 154 questions
- Companies
- 17questioned at least once
- Reporting periods
- 9with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 154 of 154 questions from 17 companies
AAgilent Technologies15 questions · 8 reporting periods · 3 of 15 challenging
Calendar 2026 Q3
You noted 5 customers. You received orders, and this is ahead of expectations, right?
Show response
Padraig sized the reshoring TAM at ~$1B through 2030 with a 1/3 win target, citing 5 of top 10 pharma wins and 15,000 installed instruments.
Calendar 2026 Q2
Pretty impressive margin print here. It looks like, volumes were slightly above the high end of your guidance. But the leverage was pretty impressive
Show response
CFO clearly attributed margin beat to Ignite (pricing, procurement, execution), volume leverage, and Americas geographic mix, with H1-to-H2 ramp at normalized 53% split.
CAM was stand out for us. On the instrument side, LCMS, GC, double digits was standout
Show response
Management provided granular CAM breakdown by sub-segment and geography, directly addressing instrument mix and Middle East risk outlook.
Calendar 2026 Q1
Can you just talk about what drives the back half step up comps to get tougher?
Show response
Adam clarified H1/H2 revenue split is 49/51, not dramatic. Padraig cited strong momentum in pharma replacement cycle, CAM secular drivers, Infinity III share gains, and robust funnels. Direct and de-dramatized the step-up.
How are you thinking about the tariff assumptions, right? Are you assuming now a global minimum of 15%?
Show response
Adam explained no guide change at 15% global minimum due to no-regret supply chain moves, pricing/surcharges, and Ignite resilience. Padraig added manufacturing moves are permanent, not tariff-dependent. Direct and confident.
Calendar 2025 Q4
Could you just quantify what is tariff versus FX dynamics on gross margins?
Show response
Rodney confirmed gross margin expansion expected. Full tariff mitigation in H2 through pricing and cost reduction. BioVectra annualization removes prior drag. Not guiding specific gross margin number. Direct.
How did orders in a backlog grow? I'm curious. I know last quarter you were speaking about stimulus, China-related stimulus
Show response
Padraig confirmed positive book-to-bill with stable order rates. SAMR tender shifted from Q1 to later in FY2026. ~$10M GACC orders expected but excluded from FY2026 guide as upside. 50% first-round stimulus win rate. Direct.
Calendar 2025 Q3
is that is that a reasonable framework on how we think about Agilent? Or are there any anything that's unique?
Show response
Padraig highlighted three Agilent differentiators vs peers: China stimulus upside with proven win rates, CDMO mix (NASD 20%+ growth, BioVectra primed for FY2026), and secular CAM exposure (reshoring, fabs, EVs). Direct competitive framing.
Did TQ benefit from from timing element here on on instrument side? The the sort of another related actually, that top line question is, you mentioned tariff rate. When when you say pricing benefit...
Show response
Padraig confirmed steady instrument improvement with high-single-digit total instruments and low-double-digit LCMS. Surcharges not yet in results, will flow through Q4 and FY2026. Direct distinction between organic pricing and tariff surcharges.
Calendar 2025 Q2
Why is it slowing down to low singles? I think you said in 3Q. And when you apply that to overall company, right, I think it's stepping down by 250 basis points
Show response
Angelica explained $15M pull-forward reversal makes normalized ACG mid-single digits. Fundamentals remain strong. Direct and clear on the distortion.
I think you had a restructuring charge, which wasn't there in prior quarters. Is this some new cost actions that hasn't been initiated?
Show response
Bob attributed GM decline to tariffs (55bps), mix, and FX. Restructuring is GAAP-only from Ignite organizational changes, excluded from non-GAAP. Clear.
Calendar 2025 Q1
is that being driven by stimulus or perhaps timing of the Chinese New Year? Maybe talk about the book-to-bill trends and what is that signaling?
Show response
Bob clearly distinguished genuine recovery from stimulus effects, highlighting LC and LCMS as primary drivers. Direct and transparent.
what is the average age of the fleet? And when you do that math, what is incremental of that few hundred million versus a normal replacement cycle?
Show response
Padraig described aging installed base and sequential improvement in December orders. Angelica added context on service and consumable attach rates.
Calendar 2024 Q4
When you look at the first half versus second half, it does assume a back half step up. We're just curious. Is that being driven by end markets normalizing?
Show response
Bob explained Lunar New Year timing, China recovery trajectory, and Infinity III replacement cycle acceleration. Clear walkthrough of H2 drivers.
Is the guide assuming free cash flow down above it, there's a timing element and on the margin sort of similar cadence question, what is Q1 assuming
Show response
Bob detailed FCF timing (CapEx peak for NASD), Q1 expense patterns, and Ignite savings cadence for H2. Comprehensive.
EWEdwards Lifesciences14 questions · 7 reporting periods · 3 of 14 challenging
Calendar 2026 Q2
Is -- have you seen an inflection in EVOQUE? And is that what's driving the strength? Or is this more broad-based when you look at the TMTT portfolio?
Show response
Chopra ranked the platforms by size and growth and detailed EVOQUE's new-center and workflow drivers, answering both parts.
What were the baseline drugs in this trial? Was it a consideration when randomizing?
Show response
Lippis directly addressed the premise, distinguishing PROGRESS from the UNLOAD heart failure trial and explaining why drug regimens are not a key variable.
Calendar 2026 Q1
Can you just maybe express your bullishness on PROGRESS and how are you handling crossovers?
Show response
Bernard declined to comment ahead of the TCT presentation, saying he does not know the PROGRESS results yet.
how you're thinking about share count here for second quarter and whether there was any weather impact
Show response
Scott said roughly $520 million was repurchased, full-year average shares are down about five million, and the Q1 weather impact was nominal.
Calendar 2025 Q4
What is, I guess, a great way to think about moderate AS? You know, when these patients are untreated, right, do they look like, low-risk TAVR patients
Show response
Bernard expressed confidence and belief but emphasized importance of waiting for clinical evidence before making claims. PROGRESS results expected at TCT. Dan Lippis noted early TAVR taught them disease is more unpredictable than assumed. PROGRESS enrolled very fast, usually a positive indicator.
On Sabre, you called out a distributor impact in Q4. Could you quantify what the impact is? Are those sales coming back in Q1
Show response
Scott confirmed one-time China distributor inventory adjustment. Still expects mid-single-digit surgical growth for 2026+. For Q1 2026, reported basis ~300bps above underlying growth from FX. First half higher than second half. Increasingly confident in 6-8% TAVR guidance.
Calendar 2025 Q3
there was a litigation charge. And it was non-GAAP, could you just remind us on what the charge was
Show response
Scott gave a general response about periodic litigation reserves without disclosing specifics. Noted it is reflected in GAAP P&L.
why isn't this performance a reflection of asymptomatic approval? I'm curious why you think the strength wouldn't sustain
Show response
Dan Lippis confirmed asymptomatic indication plays a role but the halo effect on symptomatic patients is the bigger driver. No significant evidence of asymptomatic patients entering treatment pathway yet, NCD doesn't cover them. Bernard emphasized big catalysts still ahead.
Calendar 2025 Q2
You said double-digit revenues and EPS for 2016. Do you expect operating leverage for 2026
Show response
Scott corrected: 10% is the annual average target, not the bottom of 2026 guidance range. Confirmed 50-100bps EBIT margin expansion on constant currency basis starting 2026.
Can you just walk us through what the implied back half gross margins? And I think the EPS guidance for 3Q in place, maybe a 25-ish kind of operating margins
Show response
Scott confirmed JenaValve close hoped for August (partial Q3, full Q4 impact). FX hurts gross margin but benefits EPS via translation. Tariff impact now less than half of original $0.05 estimate. Mid-20% operating margins for H2 confirmed, unchanged from prior quarter.
Calendar 2025 Q1
Are we expecting to offset, you know, that increment $0.10 to $0.15 of headwinds completely or should we be perhaps looking at the bottom half
Show response
Scott noted JenaValve close timing and integration plan uncertainties make it premature to narrow within the range. Range accommodates different scenarios.
Japan was a little light. Maybe talk about trends within Japan
Show response
Bernard acknowledged disappointing Japan results from weaker procedure growth and competitive pressure. Enhancing capabilities and positioning differentiated technology value.
Calendar 2024 Q4
given some of those items won't repeat, why shouldn't Q1 be better? Is there any one-offs outside of the extra day
Show response
Scott confirmed hurricane impact was not major. Larry explained typical end-of-year screening slowdown empties the January patient funnel.
I think there is a CED criteria. And when I look at the physician criteria, there is a cross-pollination collaboration between a variety of physicians
Show response
Bernard and Daveen explained multi-specialty team is standard care, not a procedural requirement. CED provides timely access and they don't expect it to affect rollout plans.
BAXBaxter International13 questions · 7 reporting periods · 3 of 13 challenging
Calendar 2026 Q2
can you talk about your order book within Connected Care? That business did well.
Show response
Hider gave a specific read on order book and funnel visibility and added customer-visit colour on the Dynamo stretcher.
some questions around whether any one-timers Was there any restocking benefit from IV fluid?
Show response
Hider ruled out a material restocking benefit and described the current IV solutions level as the new baseline.
Calendar 2026 Q1
excluding the comps, you guys said up low singles
Show response
Kevin Moran reiterated Q2 will face similar year-over-year headwinds as Q1 including injectables, Novum, and HST back-half weighting. Hider explained HST decline was driven by FLC timing and planned exits, while CCS was flat with PSS growth offset by Care Communications installation timing. Expects HST low single digit growth for full year, back-half weighted.
Calendar 2025 Q4
You mentioned the operating model change. Curious on what has changed from prior model. How is this model better?
Show response
Hider described delayering at top level, removing segment management, embedding functional roles in businesses for full P&L accountability. Joel confirmed free cash flow expected to improve in 2026 driven by working capital improvement, absence of hurricane-related onetime costs, and GPS-driven operating discipline. Back-half weighted similar to 2025.
Have you communicated this to customers? What have you told customers? I understand the guidance assumption, but I am curious, are customers willing to wait for a year for Novum to resolve?
Show response
Hider emphasized continued customer use with mitigating actions, Spectrum LVP as alternative on IQx platform, and upcoming PureVu launch in early Q2. Did not directly address whether customers will wait a full year. Reiterated the strong total pump portfolio.
Calendar 2025 Q3
Q4, I just want to clarify, is the implied injectables something like down mid-teens on the pharma side? What drives that? And I think guide implies operating margin declines
Show response
Joel attributed pharma weakness to U.S. premix softness and IV push shift, competitive pricing, and shifting protocols. Described a comprehensive cross-functional review including focused launch teams, active territory management, and end-to-end review processes. OI decline driven by volume impact on supply chain.
What is the issue, Andrew, that you've been able to identify, has Baxter been in touch with the FDA? When was the last communication? What has the FDA asked you or asked Baxter from a remediation p...
Show response
Joel took this question instead of Hider. Declined to specify FDA communications or remediation details, referencing publicly available field action information. Emphasized confidence in both Novum and Spectrum platforms, focus on customer support, and ramping Spectrum production as alternative.
Calendar 2025 Q2
Is it possible for you to give us a bridge, right? I think the fiscal '24 jump off of 16.5%. I know we have a number of moving parts between TSA, MSA, stranded costs
Show response
Joel bridged: tariffs down from $65M to $40M (net +$25M positive), pricing on track, but volume absorption on lower fluid manufacturing and unfavorable pharma mix are the main negatives. Lower tax rate helps on EPS line.
IV fluids are off allocation. Like why are hospitals still conserving fluids? And this Novum, I think the FDA letter noted 2 deaths. Historically, when we've had recalls, like sometimes it's taking...
Show response
Heather explained hospitals slow to change, force majeure only ended late May, and Vizient reserve program launched to reinforce supply confidence. On Novum, emphasized voluntary action on a very small subset of clinical use cases, differentiated from historical competitor recalls, and said permanent fixes are not required to resume shipping.
Calendar 2025 Q1
Can you just remind us for context, like what's been share gains over the past few quarters? Has it accelerated?
Show response
Heather confirmed low single-digit market share gains within less than a year of Novum launch. Highlighted strong pipeline of digital suites behind the platform and rebuilding customer confidence on IV solutions.
If you look at second quarter, 1% to 2% for core Baxter. That's a 350 basis point decel at the midpoint from Q1 levels
Show response
Joel attributed Q2 decel to IV conservation headwinds and HST conservatism. Noted H1 total consistent with expectations. Confirmed operating margin change from tariffs and unfavorable FX on bottom line.
Calendar 2024 Q4
Can you quantify what the headwind from Helene was in the quarter? And what drove the hurricane impact? It looks like pumps was very strong
Show response
Heather quantified $110M top-line/$0.10 EPS Helene impact, noted $45M better than expected on IV Solutions from swift recovery, and highlighted Novum IQ taking multiple points of market share.
Joel, maybe my first question on TSA and margins here. I know the optics, these are apples-to-oranges comparison rate, but the year on year, it does look margins were up 250 basis points
Show response
Joel provided detailed bridge: +40bp Helene normalization, +220bp stranded cost offset, +100bp operational improvements (pricing, mix, volume leverage), -40bp residual stranded costs, -60bp MSA dilution.
GEHCGE HealthCare13 questions · 7 reporting periods · 2 of 13 challenging
Calendar 2026 Q2
It looks like the base business ex-Flyrcado is doing really well. What's driving that?
Show response
Arduini named the specific drivers (Vizamyl, DaTscan, Cerianna, contrast) and reaffirmed the 2028 target, while cautioning the Flyrcado ramp will not be linear.
It seemed a bit abrupt for us. Maybe talk about why now and where are we in the CFO search process?
Show response
Saccaro gave his personal rationale and Arduini confirmed the search just kicked off, but neither addressed the abruptness of the timing directly.
Calendar 2026 Q1
Back half does imply a step up. And when I look at your order growth and book-to-bill, it looks like your capital book-to-bill was well north of 1.1
Show response
Pete confirmed healthy capital equipment market with U.S. mid-single-digit growth, EMEA and Rest of World up double digits. Jay added 1% orders growth against 10% comp is a strong start. Record backlog and key NPIs (Vivid Pioneer, imaging products) support H2 acceleration. PCS improvement expected from H2-loaded monitoring deals and new anesthesia product.
Talk about the $250 million number that you quoted. What does it assume? Is it assuming current inflation trends?
Show response
Jay confirmed $250M assumes current elevated cost levels persist, no additional cushion included. Offsets: pricing on new orders, transportation mode changes, measured cost actions. Price benefits weighted to H2 since current quarter sales already in backlog. Memory chips and oil/freight each ~$100M, metals and other ~$50M.
Calendar 2025 Q4
What is fiscal 'twenty-six assuming for Flurcato? And you I know you mentioned China declines
Show response
Jay declined to give specific Flyrcado guidance but noted pleased with dose progress and will share information periodically. China budgeted down in 2026 guidance within 3-4% total growth. Vijay calculated capital book-to-bill north of 1.1 and backlog up ~10%; Jay confirmed strong backlog growth but didn't confirm specific equipment book-to-bill split.
Calendar 2025 Q3
capital book-to-bill, if you will, last 7 quarters, you've ranged it around 1.12. And I know fiscal '25, some of the revenue recognition was impacted
Show response
Jay confirmed normal cancellation rates with no material changes. Trailing 4-quarter orders growth at 6%. Expects 2026 growth faster than 3% based on strength of capital book.
I saw you guys signed a distribution agreement with CDL on your pharma diagnostics side for [ Flyrcado ]
Show response
Pete confirmed CDL partnership targeting rubidium-to-Flyrcado conversion. 60-90 day typical customer transition cycle. Higher percentage conversion of CDL base moves close to $500M medium-term target.
Calendar 2025 Q2
any of these actions or things that you would call as causing regret if rates were to change, come down
Show response
Jay split actions: bucket 1 (no-regret: USMCA, bonded logistics, dual sourcing) already in place; bucket 2 (supply chain restructuring, local-for-local) waiting for trade deal clarity. No 2026 EPS guidance yet.
can you talk about capital environment across different regions, U.S., Europe and whether China has bottomed
Show response
Pete detailed U.S. aging installed base driving replacement, Europe recovery in U.K./Germany/France, China activity picking up but recovery taking longer. Jay noted equipment book-to-bill well above 1.1x for three quarters.
Calendar 2025 Q1
free cash, it was lowered by maybe $0.5 billion. Is that all cash impact
Show response
Jay confirmed FCF reduction exclusively from tariff payments. Higher costs hit inventory/cash before P&L liquidation. No other changes to free cash flow outlook.
what portion of that is U.S. to China versus China to U.S.? I think there was some talks maybe of exemptions from China
Show response
Jay quantified: $375M bilateral China impact ($0.65 of $0.85). Hypothetical 100-point bilateral reduction on May 1 would be ~$0.40 EPS benefit. No exemptions included in guidance.
Calendar 2024 Q4
Why is 2.5% to 3.5% like ex-China the right number, when Q4 -- we exited Q4 at 4% organic
Show response
Jay explained strong orders have long delivery lead times, not impacting Q1/Q2 revenues. Record backlog gives confidence but must be thoughtful about timing.
Q1, I think I heard you say flat margins. Is there anything one-off in Q1
Show response
Jay explained R&D and SG&A investment for launches (including Flyrcado salesforce expansion) will offset gross margin improvement in Q1.
MTDMettler Toledo13 questions · 7 reporting periods · 6 of 13 challenging
Calendar 2026 Q2
the implied exit rate for Q4 is somewhere between 4% to 5%, depending on the midpoint or high end of the guidance
Show response
Shawn explained the Q4 step-up is largely a tougher Q3 comp plus normal sequential flow and back-half momentum.
Calendar 2026 Q1
what was the issue in labs, and was it all tied to Middle East?
Show response
Patrick cited pipettes/academia and European chemical delays as lab headwinds, with bioprocessing remaining strong.
is that assuming academic and government improves?
Show response
Patrick said the H2 step-up is driven mostly by industrial and China, not by an assumed academia recovery.
Calendar 2025 Q4
looks like maybe half to be -- came from below the line, right, between interest expense and higher pension income
Show response
Shawn clarified FY2026 EPS raise of $0.70 (~2%) driven by Q4 beat carry-forward plus Swiss tariff reduction from 39% to 15% (just under 1% EPS benefit). Some pension accounting noise offset by FX headwind. Maintained 8-9% EPS growth.
You guys did 4% organic in Q4. I think your Q1 is implying 2% organic, correct me if I'm wrong. What causes that 4% to 2% step down
Show response
Shawn provided full Q4/Q1/FY breakdown by segment and geography. Q4 beat driven by PI in Europe. Q1 step-down from industrial (core industrial Q4 2% organic → Q1 flattish), retail normalizing (19% → high single digit), and Americas caution (4% organic → low single digit).
Calendar 2025 Q3
Your tariff headwinds should abate quite meaningfully, but should we see a more -- a little bit more robust margin expansion
Show response
Shawn explained reported margin expansion of 20-30bps masks currency-neutral +60bps due to Swiss franc strengthening against euro inflating costs. Tariff offset embedded in full year 2026.
When I look at your back half of '25, you're averaging 4.5%. So that 4% for '26 seems a step down from back half. What changes in how you think of price versus volume
Show response
Patrick attributed conservative guide to continued macro uncertainty. Shawn explained pricing steps down from 3.5% in H2 2025 to 2.5% for FY2026, so organic volume growth is modest but not a significant change from H2 2025 trend.
Calendar 2025 Q2
You did bring up services, some timing issues. Are those coming back in the back half
Show response
Patrick attributed Q2 softness to project timing and spare parts comps. Growth investments continue with more service engineers and marketing resources. Year-to-date 5% growth.
should we think of Mettler's ability to fully offset that? And related to that fiscal '26, I think some of your peers have made some comments on tax rates
Show response
Shawn confirmed confidence in 2026 mitigation with good ideas already. Tax rate expected to remain at 19% for 2026. Potential cash tax benefit from R&D capitalization being studied.
Calendar 2025 Q1
is the guide assuming you know, post the ninety-day pause for rates to tariff rates to creep back up, like, what is the guide assuming on tariffs
Show response
Shawn confirmed guidance assumes tariffs stay at current levels. No assumption of escalation or de-escalation from 90-day pause.
Q1 ex the shipping delays, you guys up 3% low singles. Q2, zero to one, what drives that step down in revenues
Show response
Shawn explained Q2 is volume low point from China caution and Americas uncertainty. Back half similar volume to first half but benefits from higher pricing flow-through.
Calendar 2024 Q4
if you look at the Q4 performance here, headline 12%, excluding the shipping comp, the underlying is 6%, Wouldn't that imply like if that's your exit rate
Show response
Patrick attributed growth to innovation and portfolio strength, acknowledged possible budget flush in Europe, denied tariff pull-forward evidence.
what is your competitive landscape in China? Do you have local competition? And then how should we think about potential risk related to China
Show response
Patrick emphasized 30-year presence, local manufacturing/R&D, broad fragmented portfolio as competitive moat limiting risk.
RVTYRevvity13 questions · 7 reporting periods · 2 of 13 challenging
Calendar 2026 Q2
Why aren't we seeing a little bit stronger fall through to the bottom line?
Show response
Management said the $0.10 EPS raise is half net tariff-refund/reinvestment and half from higher organic growth, with incremental margins in the low 40s, in line with the historical average.
Calendar 2026 Q1
when you look at the annual guide, pro forma 2 to 4 implies I think a step down to 3% for the remainder of the year. Why
Show response
Max clarified: H1 averaging ~4% pro forma, H2 requires 3-4% to hit full year 3-4%. Conservative assumptions on LS Solutions and DX in H2. Upside possible if market improvement continues.
is the organic raise, is that all driven by removal of China Immunodiagnostics or did base go up?
Show response
Max confirmed 100bps organic raise entirely from removing China IDx. No change to underlying business assumptions. EPS does not include any benefit from divestiture proceeds (deal closes in 2027).
Calendar 2025 Q4
How are you thinking about life science versus diagnostics relative to that two to three corporate?
Show response
Max provided full build: LS solutions low single digit (reagents low single digit, instruments flattish), software mid-single digits. DX: repro health mid-single digits, IDx low single digits (high single digits ex-China).
how you're thinking about deal size. I know you mentioned, you know, returns metrics have to have to, you know, clear the hurdles. What is the potential for a merger of equals?
Show response
Prahlad confirmed M&A focus on software and LS reagents. No targets yet compelling enough financially or strategically. Continued disciplined approach.
Calendar 2025 Q3
Can you elaborate that on is that, like, pharma? Is that academic and government customer base? Is that showing up in reagents or instruments?
Show response
Prahlad specified improvement is pharma/biotech instruments, not broad-based or academic. Not yet translating to widespread demand but a clear emerging trend.
should that 2% to 3% organic with 28% op margins translate to high singles EPS for '26?
Show response
Max confirmed high-single-digit EPS growth at 2-3% organic with 28% OEM, 18% tax baseline, and lower share count. Prahlad added this is before any additional capital deployment.
Calendar 2025 Q2
Was that anything else beyond DRG? Anything on VBP? Because when we're doing the math, I think the exit rate is low singles
Show response
Prahlad confirmed DRG debundling is the primary driver. Explained multiplex volume reduction as looking for a needle in half the haystack.
Can you just remind us what is your typical range? What volumes do they assume?
Show response
Max established 28% OEM baseline for FY26 with 75bps expansion at high-single-digit growth or 50bps at mid-single-digit.
Calendar 2025 Q1
can you just remind us what is pharma as a percentage of total company revenues and where is this exposure?
Show response
Pharma/biotech is 35% of revenue, mostly preclinical. Reagents continue to see sustained stabilization.
That seems slightly higher versus what we've heard from some of your peers so far. So maybe just talk about what is the updated gross margin assumption
Show response
Prahlad clarified $135M is gross without-any-mitigation scenario. Max quantified Q2 gross margin at ~60% vs historical 61.5-62.5%.
Calendar 2024 Q4
are you gaining any market share here within reagents? And how should we think of reagents growth in fiscal 2025
Show response
Prahlad confirmed share gains in reagents driven by innovation and program stickiness.
the guide of 2% to 5%, how did the segment outlooks compare relative to 3% to 5% and perhaps what drives the low-end versus the high-end?
Show response
Clear segment breakdown: Diagnostics upper mid-single digits, Life Sciences middle of low-single digits.
Show 11 more companies
DHRDanaher Corporation12 questions · 6 reporting periods · 0 of 12 challenging
Calendar 2026 Q2
Guide raise was, I think, around $0.08. Is this some conservatism, or is this a reflection on Masimo
Show response
Matt bridged the raise: better Q2 plus $0.07-$0.08 from early Masimo close, partly offset by mix/FX and a second-half hedge; direct.
Should we be looking at the upper end? I'm curious on early thoughts on FY 2027.
Show response
Matt reiterated a mid-single-digit Q4 exit and 3-4% FY, declined a firm 2027 number; partial.
Calendar 2026 Q1
Maybe just talk about sequential margins just given Q1 was such a good execution from a margin standpoint?
Show response
Gugino attributed the Q2 margin step-down to seasonal respiratory decline, incremental FX headwinds, and deliberate acceleration of growth investments from H2 into Q2 given the Q1 beat.
maybe just walk us through on this strategic rationale. I think you guys mentioned call point synergies
Show response
Blair positioned Masimo within the 3-dimensional acquisition framework: right end market, premier asset in pulse oximetry, and viable financial model. Gugino detailed $125M cost synergies and $50M revenue synergies by year 5.
Calendar 2025 Q3
your guide implies for Q4 double digits. So maybe talk about what changes sequentially from 3Q to 4Q
Show response
Matt clarified Q4 diagnostics improvement is entirely from lapping VBP and reimbursement changes that first hit in Q4 2024. Core business ex-China remains at mid-single-digits.
how are you thinking of M&A versus share repurchases, right, when you look at assets available in the deal pipeline
Show response
Strong M&A bias maintained with disciplined ROIC framework. At current levels, buybacks generate attractive returns. $2B deployed on 10M share repurchase in Q3 plus new 35M share authorization.
Calendar 2025 Q2
Was there any pull forward either in academic channels or biopharma channels
Show response
Rainer confirmed no evidence of pull-forward in either academic or biopharma channels. Plans to provide preliminary 2026 thoughts during October earnings call.
Implied growth of Q4 should accelerate to, you know, high singles, maybe 8 to 9%
Show response
Matt clarified both Q3 and Q4 guided to high-single-digits. Q4 step-up vs Q3 is normal seasonality (Q3 always lowest), not an assumed improvement in activity level.
Calendar 2025 Q1
What is Danaher's total exposure to pharma, pharma overall, including bioprocessing
Show response
Pharma R&D is a third of Life Science instruments, which is less than 10% of total sales, very small exposure. Bioprocessing at $6B is 75% commercial/Phase III, largely insulated from R&D cuts.
The $350 million of that gross headwinds, is that a full year impact or a partial year impact
Show response
Matt clarified $350M is rest-of-year with current tariffs. Split roughly 50% U.S.-to-China (mostly diagnostics assays) and 50% U.S.-from-Europe. Q2 margin step-down is respiratory seasonality, not tariffs.
Calendar 2024 Q4
Was there anything one-off in Q1, maybe which is different versus the rest of the year? I think you mentioned, Pall
Show response
Rainer explained Q1 Pall comp includes a large tens-of-millions energy project from prior year. Beyond that, trends remain consistent with Q4 exit rates across all segments.
How much of that is being contemplated in Q1 and rest of the year? And can you just remind us on - of your M&A criteria
Show response
Quantified $1.9B in buybacks across Q4/Q1 for about 8M shares. On M&A, seeing more activity and some pockets of better valuations, remain disciplined on right end-market, asset quality, and valuation.
SYKStryker Corporation12 questions · 6 reporting periods · 0 of 12 challenging
Calendar 2026 Q2
Any elongation of backlog or cancellations just given some of these concerns from cautious comments from hospitals.
Show response
Unambiguous answer on cancellations, plus context on cash flow now funding both buybacks and M and A.
Is there a bias towards share repo? I know you mentioned on the call. Maybe talk about the opportunity that you see
Show response
Quantified the existing authorization while reaffirming M and A as the number one priority, sizing dependent on deal flow.
Calendar 2026 Q1
sort of how are you looking at product versus channel play within soft tissue robotics
Show response
Kevin said Stryker is evaluating soft tissue robotics start-ups as an adjacency but does not have to pursue it. Would only enter if confident in creating value. Reprocessing business is separate.
how are you thinking about margin cadence
Show response
Preston reiterated no change to full-year margin expectations despite Q1 hiccup, with recovery expected over next 3 quarters driven by operational excellence, supply chain, and pricing.
Calendar 2025 Q4
you did bring up some destocking. So just talk about visibility on, you know, what gives us the constant destockings or any Salesforce disruption
Show response
Jason Beach confirmed sales force disruption is behind them. Q4 had slightly more destocking than anticipated but good visibility for minimal impact in Q1, with organic growth rates emerging in late Q1 into Q2.
What are you excited about when you look at '26? Feels like some of these super cycles were probably in second or third year. So what is incremental
Show response
Kevin Lobo listed Mako RPS handheld robot (initial cases this month), Vocera sync badge, OptiPly, Encompass total ankle, Artyx, and 1888 camera in development. Emphasized diversification means no single launch is make-or-break.
Calendar 2025 Q2
comps did -- what was this just comping quarter sequentially or anything else that's going on within the knee performance?
Show response
Jason confirmed nothing material beyond normal quarterly fluctuation. July off to a good start. Still a mid-single-digit market.
questions around the CapEx environment. So maybe if you could just period by the broader CapEx environment in LIFEPAK 35 launch
Show response
Jason confirmed elevated capital backlog. Kevin noted LIFEPAK 35 has strong orders, European approval exciting. Long product cycle, still contributing 3 years from now.
Calendar 2025 Q1
how should we think about progression? And I'm assuming tariff is mostly a back half impact in that $200 million, is this China versus Europe?
Show response
Preston guided to even margin flow. Tariffs more back-half loaded but offset by mitigations. China is about 2% of business. Declined to provide further geographic tariff breakdown.
Any comments on how LP 35 launch is going? I think in the past, you've commented about share gains. Curious on opportunity that you're seeing within Medical?
Show response
Kevin confirmed strong LIFEPAK 35 reception with healthy order pipeline. Over 100,000 prior generation units in installed base creating multi-year replacement tailwind.
Calendar 2024 Q4
Inari, is the maximum dilution impact here 20 basis points, Glenn? Is that what you're saying? And Spine, I think the comment you made was Spine will be absorbed
Show response
Glenn confirmed both points clearly. Inari max 20bps dilutive to margin, Spine absorbed in existing EPS guidance.
I know there was some noise around a DOJ investigation. If you could just clarify on how you got comfortable, that would be helpful
Show response
Andy acknowledged deep review of the CID risk but offered limited specifics. The fact they proceeded speaks for itself.
MDTMedtronic9 questions · 7 reporting periods · 1 of 9 challenging
Calendar 2026 Q3
I think your prior comment was about twice the rate of market growth. And I think today, you said 2.5x
Show response
Geoff raised the CAS full-year outlook to 2.5x the mid-teens market (>3x in Q2), citing Sphere-9 runway; Thierry said there is no hesitation on the MiniMed separation timing.
Calendar 2026 Q2
what are the offsets, which segments accelerate to offset CAS and drives the confidence in this 5.5%-6% organic?
Show response
Martha clarified CAS impact next year is similar to this year, with the EP market growing mid-to-high teens and Medtronic growing north of 2x the market at ~15% share. Pieton detailed offsets: cardiovascular in line with 2026, Ardian annualizing ~$100 million, every Neuroscience franchise accelerating (Stealth AXiS, neurovascular, Altaviva), MedSurg momentum, and MiniMed adding 20-25 basis points. Guidance midpoint ~5.8%.
Calendar 2026 Q1
How should we monitor the progress? Are there any goalposts that we can look forward to in tracking the launch curves for RDN and Altaviva?
Show response
Martha cited leading indicators: Altaviva with 500+ physicians trained, RDN with 200+ new accounts opened, Physician Finder up to 150 physicians (high bar: 5 cases + opt-in), 100M+ covered lives (~1/3 U.S. population). Committed to providing more concrete goalposts as launches mature.
we're looking at exit rates of 6% organic, right? And let's assume next year is north of 6%. The extra week is almost 2 points of growth. So are we looking at base organic excluding extra week some...
Show response
Pieton clarified extra week is slightly less than 2 points. Base organic growth in FY27 expected to accelerate above FY26's ~5.5% rate, with extra week additive on top. Specific calculations to follow at Q4 announcement.
Calendar 2025 Q4
do you feel like we have enough mappers now? And if is supply in a place enough where you can hit the $2 billion
Show response
Martha confirmed supply is not holding back PFA growth and mapper hiring is keeping ahead. On tibial, described 46 million U.S. overactive bladder patients, 16 million with urge incontinence. Patients choose tibial over alternatives when presented with all options.
Calendar 2025 Q2
Why is earnings growth back-end loaded? Is this a mix impact on margins? I think Q4 gross margins came in below. Was there a product mix issue?
Show response
Pieton explained Q1 seasonally lower absorption, front-loaded growth investments, and slight FX headwind. Gross margin headwinds of 80bp from CAS/Diabetes mix offset by pricing and cost improvements. Martha committed to leveraged EPS growth regardless of FX.
Calendar 2025 Q1
what gives you the confidence this is not a share loss? And I think related to that P&L management, right, this gross margin stood out. Any one-timers in gross margins?
Show response
Martha confirmed direct visibility into end-customer purchasing showing stable demand and no share loss. Corona attributed gross margin gains to COGS efficiency, pricing discipline, and some FX favorability.
Calendar 2024 Q4
the revenue per case on Affera is that 3x versus cryo?
Show response
Sean clarified revenue per case increases from additional components in PFA vs cryo, but not quite 3x. Sphere-9 saves hospitals money by eliminating need for separate mapping catheter.
You mentioned flattish growth in the quarter due to some disruption, what was the issue? When was it resolved? What gives us the confidence of strong double-digit growth in third quarter
Show response
Geoff explained third-party supplier interruption is resolved with expanded capacity, PulseSelect doubling physicians and patients, plus Sphere-9 approval all support strong double-digit Q3.
WATWaters Corporation8 questions · 4 reporting periods · 0 of 8 challenging
Calendar 2026 Q2
EPS increase of $0.05, that just reflects the second quarter beat being carried forward, right?
Show response
Chaubal explained the modest $0.05 raise: +$0.30 from organic and cost actions offset by $0.25 FX headwind; tariff refunds would net neutral.
It likely grew north of a 5% constant currency. This is well above deal model, right?
Show response
Batra rated BD execution 'A-plus' and guided to exiting 2026 at 6% or better growth for the acquired businesses, above deal model.
Calendar 2026 Q1
what was underlying organic ex days? When you say back half is 6%, is that for core organic or pro forma organic inclusive BD
Show response
Amol quantified 4 extra working days = ~2% total revenue benefit for legacy Waters, but noted chemistry and service still grew double digits even ex-days. Back half guide at 6% CC is deliberately prudent.
it looks like it was flattish, but for the period owned under Waters, it was up 5%
Show response
Vijay probed whether timing or extra days inflated the owned-period growth. Amol acknowledged extra days were factored into guidance, attributed $40M beat to execution, and noted second half guide was derisked.
Calendar 2025 Q1
Q1 very pleased with double-digit growth. Your prior guidance I think, assume something like 4% to 5% to hit the midpoint of the guidance
Show response
Management kept instrument assumption at roughly 4-5% for balance of year despite double-digit Q1 start.
Share count assumptions went up a tad versus prior guidance. Curious why no buyback assumptions within the guide
Show response
CFO noted share count increase offset by lower interest expense, net neutral to EPS.
Calendar 2024 Q4
PFAS, GLP-1, are we still assuming 30 basis points of contribution? How are you thinking about China-India within that guidance framework
Show response
Management confirmed 30bps each from GLP-1 and PFAS, 70-100bps from India, and low single-digit China assumption.
How are you incorporating some of the macro-related risks when you think about tariffs perhaps NIH spending cuts, perhaps potential cuts to agencies like EPA
Show response
Management walked through the 4.5% low end as having prudence built in, with instruments needing only 4-4.5% growth for the midpoint.
ABTAbbott Laboratories7 questions · 7 reporting periods · 0 of 7 challenging
Calendar 2026 Q2
how much visibility do you have on these Caregap programs in the back half stepping up for Exact Sciences?
Show response
Ford confirmed visibility, tied care gap timing to HEDIS credit and CMS star ratings, and separately addressed blood-based CRC screening positioning versus Cologuard sensitivity.
Calendar 2026 Q1
talk about your plans for sustaining strong growth of Cologuard. Is there an international angle here for Cologuard?
Show response
Ford outlined comprehensive Cologuard growth strategy: 50M unscreened Americans, possible screening age lowering to 40, international expansion leveraging Abbott distribution, 25% rescreen rate growing, and care gap programs tied to CMS star ratings.
Calendar 2025 Q4
how durable is this double-digit growth in a category that's, you know, a pacemaker, low single-digit growth category
Show response
Ford said global low-voltage pacing market ~$5B with Aveir at approximately 10%. US single chamber ~50% penetrated, still growing. Half of implants are dual chamber at sub-10% penetration. Third consecutive year outperforming market with 10% full-year CRM growth. On Exact Sciences, expects close on track with post-close leverage at 2.7x. Near-term M&A focus on integration plus tuck-in deals. Multicancer early detection viewed as potentially very large long-term opportunity.
Calendar 2025 Q3
where are we from a penetration standpoint? What innings are we in?
Show response
Ford said global low-voltage pacing market is approximately $5 billion with Aveir at about 10% penetration. US single chamber pacing ~50% penetrated, dual chamber sub-10%. Expects double-digit CRM growth to continue for next two years. International momentum building in Europe and Japan. Long-term aspiration to convert significant portion of market and become market leader.
Calendar 2025 Q2
What percentage of your installed base has been updated or convert to a -- where are we in the conversion cycle
Show response
Ford cited CRM growth trajectory from 7% in 2023 to 10% this quarter in a $4B global pacing market. Accounts up 50%, trained physicians up 50%, implants per day doubled. Next-gen with 25% longer battery and conduction system pacing pivotal in 2026.
Calendar 2025 Q1
What drives the back half acceleration rate when we look at Q1 starting point of 7%
Show response
Ford cited new product launches ramping, easier VBP comps in Q3/Q4 diagnostics, and lapping Q3 nutrition commercial execution challenges as three drivers of H2 acceleration.
Calendar 2024 Q4
your gross margins are still below pre-pandemic levels. So, I'm curious, when you look at the margins, how sustainable are these trends
Show response
Boudreau confirmed commodity price normalization supports continued margin expansion. Ford noted $1.5B debt paydown planned but balance sheet supports selective M&A with ROIC focus.
ILMNIllumina, Inc.7 questions · 7 reporting periods · 1 of 7 challenging
Calendar 2026 Q2
why is that stepping down from 8%? Why is 8% not sustainable?
Show response
Jacob said placements are not a one-off, explained instrument comps differ by half, and expects consumables to step up as the main 2027 driver; BioInsight already generating revenue.
Calendar 2026 Q1
I'm curious why the organic for the year wasn't raised. Is there some cautiousness that you're baking in?
Show response
Jacob framed the raise as leaning in early; Ankur clarified the ~0.5pt revenue raise puts the guide toward the higher end of the stated range.
Calendar 2025 Q4
what drives that step down from 6.5% exit rate in Q4? You know, when you Q4, clearly, clinical was standard.
Show response
Jacob and Ankur framed the 2%-4% guide off the second-half 2025 average as prudent, with clinical momentum intact and research as potential upside.
Calendar 2025 Q3
Was there any pull forward in academic and government segments?
Show response
Jacob confirmed no pull-forward and no NIH catch-up spend; Ankur said the 500bps margin goal from Analyst Day still stands as an aggregate target.
Calendar 2025 Q2
If you could just give us a bridge here, right? It looks like instruments came down by $25 million
Show response
Jacob pointed to strong early-access feedback on constellation, 5-base and spatial as a 2026 growth addition; Ankur bridged the guide (FX + China up, instruments down offset by consumables).
Calendar 2025 Q1
When I look at your change in China assumption, so it feels like almost all of it came from China reduction.
Show response
Ankur walked through the puts and takes: research ~3pp lower, clinical ~1pt offset, pricing ~1pt, plus a small FX benefit.
Calendar 2024 Q4
can you update us on what you've heard so far, what is your revenue mix in China
Show response
Jacob reframed to strategic importance and declined China business detail beyond the ~7% revenue disclosure.
HOLXHologic6 questions · 3 reporting periods · 2 of 6 challenging
Calendar 2025 Q2
The -- are we excluding -- is COVID a headwind, Steve? Are we backing that out when we say mid-singles.
Show response
Karleen clarified COVID is inconsequential to FY2026 organic growth calculation. Confirmed Fluoroscan should be backed out as a discontinued product.
Was there any timing element, I think you're annualizing at $80 million. If this thing can grow like strong double digits, right, this -- it could be a sizable organic contributor.
Show response
Steve attributed Endomag strength to commercial execution after taking over US distribution. Daily sales are incredibly steady and growing with no one-offs.
Calendar 2024 Q4
is the organic for the segment assuming down mid-singles?
Show response
Karleen confirmed Breast Health organic down mid-single digits. Q1-Q2 similar performance with improvement expected in Q3 and nice growth in Q4.
Q1 was impacted by flu shortage, right? Shouldn't that go away and numbers improve
Show response
Karleen noted seasonal Q2 step-down from deductible resets, with Surgical improving in H2 including Gynesonics contribution.
Calendar 2024 Q3
Are you seeing something now? Or is this more of a modeling assumption?
Show response
Steve confirmed seeing real pockets of impact, noting Hologic's surgical business is highly elective and thus more sensitive to hospital prioritization of emergency procedures.
how do you make the bridge to the LRP of 57. Is skeletal still a headwind here in fiscal '25
Show response
Karleen attributed the gap to transitory headwinds: skeletal stop ship, conservative respiratory planning, and IV fluid shortage. Back half acceleration expected.
BSXBoston Scientific4 questions · 4 reporting periods · 1 of 4 challenging
Calendar 2026 Q1
How you're funding this $2 billion buyback? Are you going to raise any debt? Why now?
Show response
Jon confirmed $2B buyback funded from cash on hand and Q2 cash generation. Restricted from trading through Penumbra shareholder vote on May 6, plan to execute after restriction lifts.
Calendar 2025 Q3
Q4 is down sequentially, right? Is that the incremental tariff headwind from Q3 to Q4? And how should we think of fiscal '26
Show response
CFO confirmed 100bps expansion for 2025 despite tariffs and ACURATE charges. Declined to give specific 2026 guidance, deferred to Q4 call. Committed to expanding operating margins and leveraged double-digit EPS growth.
Calendar 2025 Q1
assuming the trial is a success, how should we think of adoption? And any update on U.S. FDA submission for TAVR?
Show response
No TAVR US update, potentially more clarity in Q2. CHAMPION data expected first half 2026. Dr. Stein cited positive readout supports tripling WATCHMAN addressable market.
Calendar 2024 Q4
What percentage of PFA procedures do you think are associated with mapping?
Show response
Management described mapping as predominant in US, less prevalent in EU. Committed to open platform strategy while investing in OPAL differentiation. Declined to speculate on share targets.
ZBHZimmer Biomet4 questions · 4 reporting periods · 1 of 4 challenging
Calendar 2026 Q2
How much of this is being driven by Zimmer's tech strategy resonating in the marketplace versus any one-time effect
Show response
Ivan said the lion's share of the growth is Technology (not Bone Cement), driven by a healthy CapEx environment and a comprehensive robotics/navigation portfolio; Bone Cement is a tiny fraction with only some one-time international events.
Calendar 2026 Q1
you also made some interesting comments about you're seeing rapid increase in productivity in regions where you're seeing this transition
Show response
Ivan shared detailed metrics: 1099 reps reduced from 66% to below 60%, specialization from 25% to ~30%, top 6 distributors (40% of sales) signed 7+ year extensions, turnover in single digits vs 12% target. Active negotiations with ~40% of channel going better than expected. No material impact from Middle East, no supply disruptions, minor freight cost absorbed.
Calendar 2025 Q4
can you can you, give us a bridge from back half, right, when you did mid singles to 2% guidance at the midpoint for fiscal twenty six, how much of this is Salesforce reorg impact
Show response
Ivan confirmed the entire step-down from 5%+ to 2% midpoint is driven by U.S. salesforce transformation risk. Disruption typically occurs in early negotiation stages; once reps sign up, they stay. Five distributor changes in last 4-5 months going well. Productivity increases expected in 2027.
Calendar 2025 Q2
You raised it by 50 basis points versus prior assumptions, right, but it's still down 100 basis points year-on-year. Can you give us a bridge
Show response
Sukhi outlined four drivers of EPS guide increase in order of magnitude: (1) tariff assumption improved to $40M from $60-80M, (2) lower interest expense from better FCF and lower borrowings ($290M vs $305M), (3) operational improvements, (4) modest FX benefit. Operating margin still down YoY due to Paragon 28 but less than originally expected.
BDXBecton Dickinson3 questions · 3 reporting periods · 0 of 3 challenging
Calendar 2026 Q2
So can you just comment on the broader utilization and CapEx outlook, please?
Show response
Polen framed BD as a healthcare bellwether, citing U.S. MDS +6%, specimen management +14%, and a rising tube-to-needle testing ratio as evidence of solid utilization.
Calendar 2026 Q1
What was underlying excluding the onetimer headwinds, right, which segments did it impact on the bottom line
Show response
Tom confirmed 90% of portfolio grew around 5% while three known headwinds (China, vaccines, Alaris) offset. Vitor clarified TSA was not a P&L benefit; it was a G&A reclassification to other income line.
Calendar 2024 Q3
The 125 basis points of headwinds on pharma, biosciences in China, it looks like you're assuming essentially those 3 segments are flattish for the year
Show response
Management gave detailed breakdown of growth by segment, acknowledged headwinds but emphasized competitive positioning versus peers.
ISRGIntuitive Surgical1 question · 1 reporting period · 0 of 1 challenging
Calendar 2026 Q2
Can you talk about your exposure to Medicaid and exchanges, if you will?
Show response
Jamie said a significant portion is private/commercial pay with Medicare lower and Medicaid lower still, but had no precise ACA exposure estimate.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| A Agilent Technologies | 15 | 20%3 of 15 questions |
| EW Edwards Lifesciences | 14 | 21%3 of 14 questions |
| BAX Baxter International | 13 | 23%3 of 13 questions |
| GEHC GE HealthCare | 13 | 15%2 of 13 questions |
| MTD Mettler Toledo | 13 | 46%6 of 13 questions |
| RVTY Revvity | 13 | 15%2 of 13 questions |
| DHR Danaher Corporation | 12 | 0%none of 12 questions |
| SYK Stryker Corporation | 12 | 0%none of 12 questions |
| MDT Medtronic | 9 | 11%1 of 9 questions |
| WAT Waters Corporation | 8 | 0%none of 8 questions |
- AAgilent Technologies · 15 questions20%3 of 15 questions
- EWEdwards Lifesciences · 14 questions21%3 of 14 questions
- BAXBaxter International · 13 questions23%3 of 13 questions
- GEHCGE HealthCare · 13 questions15%2 of 13 questions
- MTDMettler Toledo · 13 questions46%6 of 13 questions
- RVTYRevvity · 13 questions15%2 of 13 questions
- DHRDanaher Corporation · 12 questions0%none of 12 questions
- SYKStryker Corporation · 12 questions0%none of 12 questions
- MDTMedtronic · 9 questions11%1 of 9 questions
- WATWaters Corporation · 8 questions0%none of 8 questions
Show all 17 companies
| Company | Questions | Challenge rate |
|---|---|---|
| ABT Abbott Laboratories | 7 | 0%none of 7 questions |
| ILMN Illumina, Inc. | 7 | 14%1 of 7 questions |
| HOLX Hologic | 6 | 33%2 of 6 questions |
| BSX Boston Scientific | 4 | 25%1 of 4 questions |
| ZBH Zimmer Biomet | 4 | 25%1 of 4 questions |
| BDX Becton Dickinson | 3 | 0%none of 3 questions |
| ISRG Intuitive Surgical | 1 | —Rate withheld: fewer than 3 questions |
- ABTAbbott Laboratories · 7 questions0%none of 7 questions
- ILMNIllumina, Inc. · 7 questions14%1 of 7 questions
- HOLXHologic · 6 questions33%2 of 6 questions
- BSXBoston Scientific · 4 questions25%1 of 4 questions
- ZBHZimmer Biomet · 4 questions25%1 of 4 questions
- BDXBecton Dickinson · 3 questions0%none of 3 questions
- ISRGIntuitive Surgical · 1 question—rate withheld: under 3 questions
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q3 | 3 | 33%1 of 3 questions | 2 |
| 2024 Q4 | 25 | 24%6 of 25 questions | 14 |
| 2025 Q1 | 22 | 14%3 of 22 questions | 13 |
| 2025 Q2 | 22 | 9%2 of 22 questions | 13 |
| 2025 Q3 | 17 | 24%4 of 17 questions | 10 |
| 2025 Q4 | 17 | 18%3 of 17 questions | 11 |
| 2026 Q1 | 24 | 17%4 of 24 questions | 15 |
| 2026 Q2 | 22 | 9%2 of 22 questions | 15 |
| 2026 Q3 | 2 | 0%none of 2 questions | 2 |
- 2024 Q33 questions · challenge rate 33% (1 of 3 questions) · 2 companies
- 2024 Q425 questions · challenge rate 24% (6 of 25 questions) · 14 companies
- 2025 Q122 questions · challenge rate 14% (3 of 22 questions) · 13 companies
- 2025 Q222 questions · challenge rate 9% (2 of 22 questions) · 13 companies
- 2025 Q317 questions · challenge rate 24% (4 of 17 questions) · 10 companies
- 2025 Q417 questions · challenge rate 18% (3 of 17 questions) · 11 companies
- 2026 Q124 questions · challenge rate 17% (4 of 24 questions) · 15 companies
- 2026 Q222 questions · challenge rate 9% (2 of 22 questions) · 15 companies
- 2026 Q32 questions · challenge rate 0% (none of 2 questions) · 2 companies
Topics
Topics tagged on this analyst’s questions.
- Revenue Growth53
- Guidance Reliability46
- Demand35
- Margin31
- Product Launch22
- Competitive Dynamics20
- M&A18
- Trade Tariffs16
- Innovation & R&D10
- Capital Allocation9
Show all 19 topics
- Geographic Expansion9
- Regulation Policy8
- Capex Investment7
- Supply Chain7
- Macroeconomic5
- Pricing4
- Cost Pressure4
- Inventory2
- Fx2